Researchers want to see if a new drug, alvelestat, improves the symptoms of lung disease caused by COPD due to alpha-1 antitrypsin deficiency (AATD), as well as symptoms of the AATD.
Who Can Participate
People between the ages of 18-80 with chronic obstructive pulmonary disease (COPD) due to alpha-1 antitrypsin deficiency (AATD) may be eligible to participate.
Age: 18-80 Gender Any
Estimated Time Commitment
Payment & Reimbursement
Travel Reimbursement Available
For more information, contact:
National Jewish Main Campus, Denver, CO
National Institutes of Health, University of Alabama at Birmingham
Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit.
Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study.
Robert A. Sandhaus, MD, PhD, FCCP
Request more Information
By completing this form, you agree to learn more about this study and see if you qualify.